Drugs

, Volume 70, Issue 3, pp 355–376 | Cite as

Trabectedin

A Review of its Use in Soft Tissue Sarcoma and Ovarian Cancer
Adis Drug Evaluation

Abstract

Trabectedin (Yondelis®) is a tetrahydroisoquinoline molecule that was originally derived from a marine organism. It is indicated in the EU and many other countries for use in patients with advanced soft-tissue sarcoma (STS) who have progressed despite receiving previous treatment with anthracyclines and ifosfa-mide or in those who are unable to receive these agents. It is also approved in the EU in combination with pegylated liposomal doxorubicin for the treatment of platinum-sensitive, recurrent ovarian cancer. In addition, trabectedin holds orphan drug status for the treatment of advanced, recurrent STS in the US, Switzerland and Korea, and for the treatment of advanced, recurrent ovarian cancer in the US and Switzerland.

Clinical trials showed that intravenous trabectedin was effective in chemotherapy-experienced patients with advanced, recurrent liposarcoma or leiomyosarcoma, and results from a retrospective analysis suggest that the drug may be particularly effective in patients with advanced myxoid liposarcoma. In addition, coadministration of trabectedin with pegylated liposomal doxorubicin was associated with a significantly longer progression-free survival (6 weeks) than pegylated liposomal doxorubicin monotherapy in patients with recurrent ovarian cancer after failure of first-line, platinum-based chemotherapy. The tolerability profile of trabectedin was manageable in clinical trials, and the tolerability profile of concomitant trabectedin and pegylated liposomal doxorubicin was generally consistent with that of each agent alone. Results to date indicate that trabectedin is a valuable addition to the group of second-line antineoplastic agents available for the treatment of advanced, recurrent STS, and that it is a beneficial treatment for recurrent ovarian cancer after failure of first-line, platinum-based chemotherapy when administered in conjunction with pegylated liposomal doxorubicin.

References

  1. 1.
    Schöffski P, Dumez H, Wolter P, et al. Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcoma. Expert Opin Pharmacother 2008 Jun; 9(9): 1609–18PubMedCrossRefGoogle Scholar
  2. 2.
    Casali PG, Jost L, Sleijfer S, et al. Soft tissue sarcomas: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008 May; 19 Suppl. 2: ii89–93PubMedCrossRefGoogle Scholar
  3. 3.
    Hartmann JT, Patel S. Recent developments in salvage chemotherapy for patients with metastatic soft tissue sarcoma. Drugs 2005; 65(2): 167–78PubMedCrossRefGoogle Scholar
  4. 4.
    Clark MA, Fisher C, Judson I, et al. Soft-tissue sarcomas in adults. N Engl J Med 2005 Aug 18; 353: 701–11PubMedCrossRefGoogle Scholar
  5. 5.
    Cancer Research UK. Statistics and outlook for soft tissue sarcoma [online]. Available from URL: http://www.cancerhelp.org.uk/help/default.asp?page=4569 [Accessed 2010 Jan 20]
  6. 6.
    Fayette J, Coquard IR, Alberti L, et al. ET-743: a novel agent with activity in soft-tissue sarcomas. Curr Opin Oncol 2006; 18(4): 347–53PubMedCrossRefGoogle Scholar
  7. 7.
    Carter NJ, Keam SJ. Trabectedin: a review of its use in the management of soft tissue sarcoma and ovarian cancer. Drugs 2007; 67(15): 2257–76PubMedCrossRefGoogle Scholar
  8. 8.
    Barthomeuf C, Bourguet-Kondracki M-L, Kornprobst J-M. Marine metabolites overcoming or circumventing multidrug resistance mediated by ATP-dependent transporters: a new hope for patient with tumors resistant to conventional chemotherapy. Anticancer Agents Med Chem 2008; 8(8): 886–903PubMedCrossRefGoogle Scholar
  9. 9.
    Cvetkovic RS, Figgitt DP, Plosker GL. ET-743 [published erratum appears in Drugs 2002; 62(11): 1634]. Drugs 2002; 62(8): 1185–92PubMedCrossRefGoogle Scholar
  10. 10.
    Cuevas C, Francesch A. Development of Yondelis® (trabectedin, ET-743): asemisynthetic process solves the supply problem. Nat Prod Rep 2009 Mar; 26(3): 322–37PubMedCrossRefGoogle Scholar
  11. 11.
    Simoens C, Korst AE, De Pooter CM, et al. In vitro interaction between ecteinascidin 743 (ET-743) and radiation, in relation to its cell cycle effects. Br J Cancer 2003 Dec 15; 89(12): 2305–11PubMedCrossRefGoogle Scholar
  12. 12.
    Friedman D, Hu Z, Kolb EA, et al. Ecteinascidin-743 inhibits activated but not constitutive transcription. Cancer Res 2002 Jun 15; 62(12): 3377–81PubMedGoogle Scholar
  13. 13.
    Herrero AB, Martin-Castellanos C, Marco E, et al. Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of anti-tumor trabectedin. Cancer Res 2006; 66(16): 8155–62PubMedCrossRefGoogle Scholar
  14. 14.
    Takebayashi Y, Pourquier P, Zimonjic DB, et al. Anti-proliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med 2001 Aug; 7(8): 961–6PubMedCrossRefGoogle Scholar
  15. 15.
    Tavecchio M, Simone M, Erba E, et al. Role of homologous recombination in trabectedin-induced DNA damage. Eur J Cancer 2008 Mar; 44(4): 609–18PubMedCrossRefGoogle Scholar
  16. 16.
    Soares DG, Escargueil AE, Poindessous V, et al. Replication and homologous recombination repair regulate DNA double-strand break formation by the antitumor alkylator ecteinascidin 743. Proc Natl Acad Sci U S A 2007 Aug; 104(32): 13062–7PubMedCrossRefGoogle Scholar
  17. 17.
    Casado JA, Río P, Marco E, et al. Relevance of the Fanconi anemia pathway in the response of human cells to trabectedin. Mol Cancer Ther 2008 May; 7(5): 1309–18PubMedCrossRefGoogle Scholar
  18. 18.
    Guirouilh-Barbat J, Redon C, Pommier Y. Transcriptioncoupled DNA double-strand breaks are mediated via the nucleotide excision repair and the Mre11-Rad50-Nbs1 complex. Mol Biol Cell 2008 Sep; 19(9): 3969–81PubMedCrossRefGoogle Scholar
  19. 19.
    Aune GJ, Takagi K, Sordet O, et al. Von Hippel-Lindau-coupled and transcription-coupled nucleotide excision repair-dependent degradation of RNA polymerase II in response to trabectedin. Clin Cancer Res 2008 Oct 15; 14(20): 6449–55PubMedCrossRefGoogle Scholar
  20. 20.
    Forni C, Minuzzo M, Virdis E, et al. Trabectedin (ET-743) promotes differentiation in myxoid liposarcoma tumors. Mol Cancer Ther 2009 Feb; 8(2): 449–57PubMedCrossRefGoogle Scholar
  21. 21.
    Li WW, Takahashi N, Jhanwar S, et al. Sensitivity of soft tissue sarcoma cell lines to chemotherapeutic agents: identification of ecteinascidin-743 as a potent cytotoxic agent. Clin Cancer Res 2001 Sep 1; 7(9): 2908–11PubMedGoogle Scholar
  22. 22.
    Romero J, Zapata I, Córdoba S, et al. In vitro radio-sensitisation by trabectedin in human cancer cell lines. Eur J Cancer 2008 Aug; 44(12): 1726–33PubMedCrossRefGoogle Scholar
  23. 23.
    Takahashi N, Li WW, Banerjee D, et al. Sequence-dependent enhancement of cytotoxicity produced by ecteinascidin 743 (ET-743) with doxorubicin or paclitaxel in soft tissue sarcoma cells. Clin Cancer Res 2001 Oct 1; 7(10): 3251–7PubMedGoogle Scholar
  24. 24.
    D’Incalci M, Colombo T, Ubezio P, et al. The combination of yondelis and cisplatin is synergistic against human tumor xenografts. Eur J Cancer 2003; 39: 1920–6PubMedCrossRefGoogle Scholar
  25. 25.
    Riccardi A, Meco D, Ubezio P, et al. Combination of trabectedin and irinotecan is highly effective in a human rhabdomyosarcoma xenograft. Anticancer Drugs 2005; 16(8): 811–5PubMedCrossRefGoogle Scholar
  26. 26.
    Meco D, Colombo T, Ubezio P, et al. Effective combination of ET-743 and doxorubicin in sarcoma: preclinical studies. Cancer Chemother Pharmacol 2003 Aug; 52(2): 131–8PubMedCrossRefGoogle Scholar
  27. 27.
    Gore L, Rivera E, Lavallee K, et al. Phase I combination study of trabectedin (T) and capecitabine (C) in patients with advanced malignancies [abstract no. 2079]. J Clin Oncol 2006 Jun 20; 24 (18 Suppl. 1): 98sGoogle Scholar
  28. 28.
    Vidal L, García-Martín M, Tan S, et al. Phase I combination study of trabectedin and carboplatin in advanced solid tumours [abstract no. 396P]. Ann Oncol 2004; 15 Suppl. 3 iii106Google Scholar
  29. 29.
    Von Mehren M, Buck D, Temmer E, et al. Phase I study of trabectedin (T) in combination with docetaxel (D) in patients with advanced malignancies [abstract no. 2068]. J Clin Oncol 2006 Jun 20; 24 (18 Suppl. 1): 96sGoogle Scholar
  30. 30.
    Papadopoulos KP, Chu Q, Patnaik A, et al. Phase I and pharmacokinetics (PK) study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumors [abstract no. 2029]. J Clin Oncol 2006 Jun 20; 24 (18 Suppl. 1): 86Google Scholar
  31. 31.
    Sessa C, Perotti A, Noberasco C, et al. Phase I clinical and pharmacokinetic study of trabectedin and doxorubicin in advanced soft tissue sarcoma and breast cancer. Eur J Cancer 2009 May; 45(7): 1153–61PubMedCrossRefGoogle Scholar
  32. 32.
    Blay J-Y, von Mehren M, Samuels BL, et al. Phase I combination study of trabectedin and doxorubicin in patients with soft-tissue sarcoma. Clin Cancer Res 2008 Oct 15; 14(20): 6656–62PubMedCrossRefGoogle Scholar
  33. 33.
    Sessa C, Cresta S, Noberasco C, et al. Phase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumours. Eur J Cancer 2009 Aug; 45(12): 2116–22PubMedCrossRefGoogle Scholar
  34. 34.
    Messersmith WA, Jimeno A, Ettinger D, et al. Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors. Cancer Chemother Pharmacol 2008 Dec; 63(1): 181–8PubMedCrossRefGoogle Scholar
  35. 35.
    von Mehren M, Schilder RJ, Cheng JD, et al. A phase I study of the safety and pharmacokinetics of trabectedin in combination with pegylated liposomal doxorubicin in patients with advanced malignancies. Ann Oncol 2008; 19(10): 1802–9CrossRefGoogle Scholar
  36. 36.
    Jimeno J, Schöffski P, Casali P, et al. Personalized therapy with trabectedin (Yondelis®) in advanced pre-treated sarcomas [abstract no. 7505]. EJC Supplements 2007 Sep; 5(4): 403–4Google Scholar
  37. 37.
    HUGO Gene Nomenclature Committee. Approved gene names [online]. Available from URL: http://www.genenames.org/index.html [Accessed 2010 Jan 20]
  38. 38.
    Grosso F, Sanfilippo R, Virdis E, et al. Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution series. Ann Oncol 2009 Aug; 20(8): 1439–44PubMedCrossRefGoogle Scholar
  39. 39.
    Gronchi A, Palmerini E, Demetri G, et al. A phase II clinical trial of neoadjuvant trabectedin in patients with non metastic advanced myxoid/round cell liposarcoma (MRCL) [abstract no. 9400]. Eur J Cancer Suppl 2009 Sep; 7 Suppl. 2: 590CrossRefGoogle Scholar
  40. 40.
    Grosso F, Jones RL, Demetri GD, et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol 2007 Jul; 8(7): 595–602PubMedCrossRefGoogle Scholar
  41. 41.
    Allavena P, Signorelli M, Chieppa M, et al. Anti-inflammatory properties of the novel antitumor agent Yondelis® (trabectedin): inhibition of marcophage differentiation and cytokine production. Cancer Res 2005 Apr 1; 65(7): 2964–71PubMedCrossRefGoogle Scholar
  42. 42.
    Donald S, Verschoyle RD, Greaves P, et al. Complete protection by high-dose dexamethasone against the hepatotoxicity of the novel antitumor drug Yondelis® (ET-743) in the rat. Cancer Res 2003 Sep 15; 63(18): 5902–8PubMedGoogle Scholar
  43. 43.
    Lee JK, Leslie EM, Zamek-Gliszczynski MJ, et al. Modulation of trabectedin (ET-743) hepatobiliary disposition by multidrug resistance-associated proteins (Mrps) may prevent hepato-toxicity. Toxicol Appl Pharmacol 2008 Apr 1; 228(1): 17–23PubMedCrossRefGoogle Scholar
  44. 44.
    Fetterly GJ, Owen JS, Stuyckens K, et al. Semimechanistic pharmacokinetic/pharmacodynamic model for hepato-protective effect of dexamethasone on transient transaminitis after trabectedin (ET-743) treatment. Cancer Chemother Pharmacol 2008 Jun; 62(1): 135–47PubMedCrossRefGoogle Scholar
  45. 45.
    Pharma Mar SA. Trabectedin (Yondelis®): summary of product characteristics [online]. Available from URL: http://www.ema.europa.eu/humandocs/PDFs/EPAR/yondelis/emea-combined-h773en.pdf[Accessed 2010 Jan 19]
  46. 46.
    Puchalski TA, Ryan DP, Garcia-Carbonero R, et al. Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity. Cancer Chemother Pharmacol 2002 Oct; 50(4): 309–19PubMedCrossRefGoogle Scholar
  47. 47.
    Garcia-Carbonero R, Supko JG, Manola J, et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol 2004 Apr 15; 22(8): 1480–90PubMedCrossRefGoogle Scholar
  48. 48.
    del Campo JM, Pardo B, Cervantes A, et al. Pharmacokinetics of trabectedin in women with recurrent ovarian cancer. EJC Supplements 2007 Sep; 5(4): 321Google Scholar
  49. 49.
    van Kesteren C, Cvitkovic E, Taamma A, et al. Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study. Clin Cancer Res 2000 Dec 1; 6(12): 4725–32PubMedGoogle Scholar
  50. 50.
    Beumer JH, Rademaker-Lakhai JM, Rosing H, et al. Metabolism of trabectedin (ET-743, Yondelis®) in patients with advanced cancer. Cancer Chemother Pharmacol 2007 Jun; 59(6): 825–37PubMedCrossRefGoogle Scholar
  51. 51.
    Salazar R, Pardo B, Majem M, et al. Phase I clinical and pharmacological trial of trabectedin (T) in 3 hour infusion every 3 weeks (3h/q3w) in patients with advanced cancer and hepatic function disorder [abstract no. 2080]. J Clin Oncol 2006 Jun 20; 24 (18 Suppl. 1): 99Google Scholar
  52. 52.
    Beumer JH, Lopez-Lazaro L, Schellens JHM, et al. Evaluation of human plasma protein binding of trabectedin (Yondelis®, ET-743). Curr Clin Pharmacol 2009 Jan; 4(1): 38–42PubMedCrossRefGoogle Scholar
  53. 53.
    Brandon EFA, Sparidans RW, Guijt K-J, et al. In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis®, Trabectedin®), a novel marine anti-cancer drug. Invest New Drugs 2006; 24: 3–14PubMedCrossRefGoogle Scholar
  54. 54.
    Vermeir M, Hemeryck A, Cuyckens F, et al. In vitro studies on the metabolism of trabectedin (Yondelis®) in monkey and man, including human CYP reaction phenotyping. Biochem Pharmacol 2009; 77: 1642–54PubMedCrossRefGoogle Scholar
  55. 55.
    Brandon EFA, Meijerman I, Klijn JS, et al. In-vitro cytotoxicity of ET-743 (trabectedin, Yondelis®), a marine anti-cancer drug, in the Hep G2 cell line: influence of cytochrome P450 and phase II inhibition, and cytochrome P450 induction. Anticancer Drugs 2005; 16: 935–43PubMedCrossRefGoogle Scholar
  56. 56.
    Beumer JH, Franke NE, Tolboom R, et al. Disposition and toxicity of trabectedin (ET-743) in wild-type and mdr1 gene (P-gp) knock-out mice. Invest New Drugs. Epub 2009 Feb 24Google Scholar
  57. 57.
    Hing J, Perez-Ruixo JJ, Stuyckens K, et al. Mechanism-based pharmacokinetic/pharmacodynamic meta-analysis of trabectedin (ET-743, Yondelis®) induced neutropenia. Clin Pharmacol Ther 2008 Jan; 83(1): 130–43PubMedCrossRefGoogle Scholar
  58. 58.
    Perez-Ruixo JJ, Zannikos P, Hirankarn S, et al. Population pharmacokinetic meta-analysis of trabectedin (ET-743, Yondelis®) in cancer patients. Clin Pharmacokinet 2007; 46(10): 867–84PubMedCrossRefGoogle Scholar
  59. 59.
    Demetri GD, Chawla SP, von Mehren M, et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol 2009 Sep; 27(25): 4188–96. Plus supplementary material available from URL: http://jco.ascopubs.org/cgi/content/full/27/25/4188 [Accessed 2010 Jan 20]PubMedCrossRefGoogle Scholar
  60. 60.
    Chawla S, Blay JY, Schuetze S, et al. Efficacy of second-line trabectedin in patients with advanced liposarcomas and leiomyosarcomas progressing despite prior conventional chemotherapy [abstract no. 9427]. Eur J Cancer Suppl 2009 Sep; 7 Suppl. 2: 598CrossRefGoogle Scholar
  61. 61.
    Sanfilippo R, Grosso F, Virdis E, et al. Rechallenge with trabectedin in patients with responding myxoid liposarcoma [abstract no. 10575]. 45th Annual Meeting of the American Society of Clinical Oncology; 2009 May 29–Jun 2; Orlando (FL)Google Scholar
  62. 62.
    Yovine A, Riofrio M, Blay JY, et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol 2004 Mar 1; 22(5): 890–9PubMedCrossRefGoogle Scholar
  63. 63.
    Le Cesne A, Blay JY, Judson I, et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol 2005 Jan 20; 23(3): 576–84PubMedCrossRefGoogle Scholar
  64. 64.
    Demetri G, Blay JY, Yovine A, et al. Efficacy and safety of trabectedin in soft tissue sarcoma (STS) are independent of patient age [abstract no. 9402]. Eur J Cancer Suppl 2009 Sep; 7 Suppl. 2: 590CrossRefGoogle Scholar
  65. 65.
    Le Cesne A, Gianni L, Maki R, et al. Translocation-related sarcomas (TRS): a retrospective analysis of activity with trabectedin [abstract no. 9401]. Eur J Cancer Suppl 2009 Sep; 7 Suppl. 2: 590CrossRefGoogle Scholar
  66. 66.
    Johnson & Johnson Pharmaceutical Research & Development, L.L.C. A study of the safety and effectiveness of trabectedin for the treatment of localized myxoid/round liposarcoma [ClinicalTrials.gov identifier NCT00579501]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov [Accessed 2010 Jan 20]
  67. 67.
    Johnson & Johnson Pharmaceutical Research & Development, L.L.C. A study to provide access to trabectedin in patients with soft tissue sarcoma who have persistent or recurrent disease and who are not expected to benefit from currently available standard of care treatment [Clinical-Trials.gov identifier NCT00210665]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov [Accessed 2010 Jan 20]
  68. 68.
    Johnson & Johnson Pharmaceutical Research & Development, L.L.C. A study of the safety and effectiveness of trabectedin versus doxorubicin-based chemotherapy in patients with translocation-related sarcomas (TRS) [ClinicalTrials.gov identifier NCT00796120]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov [Accessed 2010 Jan 20]
  69. 69.
    Lau L, Supko JG, Blaney S, et al. A phase I and pharmacokinetic study of ecteinascidin-743 (Yondelis®) in children with refractory solid tumors: a Children’s Oncology Group study. Clin Cancer Res 2005 Jan 15; 11(2): 672–7PubMedGoogle Scholar
  70. 70.
    National Cancer Institute (NCI). Ecteinascidin 743 in treating young patients with recurrent or refractory soft tissue sarcoma or Ewing’s family of tumors. [Clinical-Trials.gov identifier NCT00070109]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://clinicaltrials.gov [Accessed 2010 Jan 20]
  71. 71.
    Monk BJ, Herzog TJ, Kaye S, et al. Trabectedin plus pegylated liposomal doxorubicin in recurrent ovarian cancer. J Clin Oncol In pressGoogle Scholar
  72. 72.
    European Medicines Agency. Assessment report for Yondelis® (EMEA/640507/2009) [online]. Available from URL: http://www.ema.europa.eu/humandocs/PDFs/EPAR/yondelis/EMEA-H-773-II-08-AR.pdf [Accessed 2010 Jan 19]
  73. 73.
    Del Campo JM, Roszak A, Bidzinski M, et al. Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5mg/m2 24-hour or 1.3 mg/m2 3-hour) to patients with relapsed, platinum-sensitive, advanced ovarian cancer. Ann Oncol 2009 Nov; 20(11): 1794–802PubMedCrossRefGoogle Scholar
  74. 74.
    Krasner CN, McMeekin DS, Chan S, et al. A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens. Br J Cancer 2007 Dec 17; 97(12): 1618–24PubMedCrossRefGoogle Scholar
  75. 75.
    Sessa C, De Braud F, Perotti A, et al. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails. J Clin Oncol 2005 Mar 20; 23(9): 1867–74PubMedCrossRefGoogle Scholar
  76. 76.
    Bidzinski M, Poveda A, Vermorken J, et al. Influence of an independent review on PFS and response assessments in a phase III clinical trial in relapsed ovarian cancer [abstract no. i8064]. Eur J Cancer Suppl 2009 Sep; 7 Suppl. 2: 468CrossRefGoogle Scholar
  77. 77.
    Herzog TJ, Vermorken JB, Pujade-Lauraine E, et al. Correlation of CA-125 and RECIST evaluation in recurrent ovarian cancer (ROC): results from a randomized phase III study of trabectedin (T) with pegylated liposomal doxorubicin (PLD) versus PLD alone. 45th Annual Meeting of the American Society of Clinical Oncology; 2009 May 29–Jun 2; Orlando (FL)Google Scholar
  78. 78.
    Poveda A, Kaye SB, McCormack RT, et al. Circulating tumor cells (CTC) in a study of relapsed/recurrent advanced ovarian cancer: an exploratory analysis in the ova-301 phase 3 study of pegylated liposomal doxorubicin (PLD) compared with trabectedin and PLD [abstract no. 5551]. 45th Annual Meeting of the American Society of Clinical Oncology; 2009 May 29–Jun 2; Orlando (FL)Google Scholar
  79. 79.
    Poveda A, Kaye S, Herzog T, et al. Correlation of RNA expression of DNA repair genes with clinical outcomes of advanced ovarian cancer (OC) pts treated with pegylated liposomal doxorubicin (PLD) vs trabectedin+PLD in the ET743-OVA-301 clinical trial [abstract no. 8005]. Eur J Cancer Suppl 2009 Sep; 7 Suppl. 2: 451–2CrossRefGoogle Scholar
  80. 80.
    Krasner CN, Poveda A, Herzog T, et al. Health-related quality of life/patient-reported outcomes in relapsed ovarian cancer: results from a randomized phase III study of trabectedin with pegylated liposomal doxorubicin (PLD) versus PLD alone [abstract no. 5526]. 45th Annual Meeting of the American Society of Clinical Oncology; 2009 May 29–Jun 2; Orlando (FL)Google Scholar
  81. 81.
    McMeekin S, del Campo JM, Colombo N, et al. Trabectedin (T) in relapsed advanced ovarian cancer (ROC): a pooled analysis of three phase II studies [abstract no. 5579]. J Clin Oncol 2007 Jun 20; 25 (18 Suppl. 1): 293s. Plus oral presentation and poster presented at the 43rd Annual Meeting of the American Society of Clinical Oncology; 2007 Jun 1–5; Chicago (IL)Google Scholar
  82. 82.
    Ludwig J, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 2005 Nov;5(11): 845–56PubMedCrossRefGoogle Scholar
  83. 83.
    Demetri GD, Schuetze S, Blay J-Y, et al. Long-term results of a randomized phase II study of trabectedin by two different dose and schedule regimens in patients with advanced liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide [abstract no. 10509 plus oral presentation]. 45th Annual Meeting of the American Society of Clinical Oncology; 2009 May 29–Jun 2; Orlando (FL)Google Scholar
  84. 84.
    Vergote I, Vermorken J, Pujade-Lauraine E, et al. Safety analysis of trabectedin in combination with pegylated liposomal doxorubicin (PLD) vs PLD alone in ovarian cancer patients 65 years of age and older [abstract no. 8028]. Eur J Cancer Suppl 2009 Sep; 7 Suppl. 2: 458CrossRefGoogle Scholar
  85. 85.
    Grosso F, Dileo P, Sanfilippo R, et al. Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma. Eur J Cancer 2006 Jul; 42(10): 1484–90PubMedCrossRefGoogle Scholar
  86. 86.
    Ortho Biotech Products. Doxil (doxorubicin HCl liposome injection) for intravenous infusion: US prescribing information [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/050718s033lbl.pdf [Accessed 2010 Jan 20]
  87. 87.
    SP Europe. Caelyx 2 mg/mL concentrate for solution for infusion: EU prescribing information [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/Caelyx/H-089-PI-en.pdf[Accessed 2010 Jan 20]
  88. 88.
    Pharmamar. Yondelis® has been approved for the treatment of ovarian cancer and soft tissue sarcoma by the Philippines [online]. Available from URL: http://translate.google.co.nz/translate?hl=en&sl=es&u=http://www.pharmamar.com/&ei=onVaSqPpLYXQtAOb0tmDCw&sa=X&oi=translate&resnum=1&ct=result&prev=/search%3Fq%3DPharmamar%26hl%3Den [Accessed 2010 Jan 20]Google Scholar
  89. 89.
    Nielsen OS, Blay J-Y, Judson IR, et al. Metastatic soft tissue sarcoma in adults: prognosis and treatment options. Am J Cancer 2003; 2(3): 211–21CrossRefGoogle Scholar
  90. 90.
    Kopp H-G, Patel S, Brücher B, et al. Potential combination chemotherapy approaches for advanced adulttype soft-tissue sarcoma. Am J Clin Dermatol 2008; 9(4): 207–17PubMedCrossRefGoogle Scholar
  91. 91.
    Wagner A. Treatment of advanced soft tissue sarcoma: conventional agents and promising new drugs. JNCCN 2007 Apr; 5(4): 401–10PubMedGoogle Scholar
  92. 92.
    Garcia-Carbonero R, Supko JG, Maki RG, et al. Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. J Clin Oncol 2005 Aug 20; 23(24): 5484–92PubMedCrossRefGoogle Scholar
  93. 93.
    Van Glabbeke M, Verweij J, Judson I, et al. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer 2002 Mar; 38(4): 543–9PubMedCrossRefGoogle Scholar
  94. 94.
    von Mehren M. Trabectedin: a targeted chemotherapy? [letter]. Lancet Oncol 2007 Jul; 8(7): 565–7CrossRefGoogle Scholar
  95. 95.
    Nijhuis P, Schaapveld M, Otter R, et al. Epidemiological aspects of soft tissue sarcomas (STS): consequences for the design of clinical STS trials. Eur J Cancer 1999; 35(12): 1705–10PubMedCrossRefGoogle Scholar
  96. 96.
    Cooper N, Quinn MJ, Rachet B, et al. Survival from cancer of the ovary in England and Wales up to 2001. Br J Cancer 2008 Sep 23; 99 Suppl. 1: S70–2PubMedCrossRefGoogle Scholar
  97. 97.
    Aebi S, Castiglione M. Epithelial ovarian carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008; 19 Suppl. 2: ii4–16CrossRefGoogle Scholar
  98. 98.
    Aletti GD, Gallenberg MM, Cliby WA, et al. Current management strategies for ovarian cancer. Mayo Clin Proc 2007 Jun; 82(6): 751–70PubMedGoogle Scholar
  99. 99.
    Bhoola S, Hoskins WJ. Diagnosis and management of epithelial ovarian cancer. Obstet Gynecol 2006 Jun; 107(6): 1399–410PubMedCrossRefGoogle Scholar
  100. 100.
    Cancer Research UK. Ovarian cancer survival statistics [online]. Available from URL: http://info.cancerresearchuk.org/cancerstats/types/ovary/survival/ [Accessed 2010 Jan 20]
  101. 101.
    Morgan RJ, Alvarez RD, Armstrong DK, et al. Clinical practice guidelines in oncology: ovarian cancer. J Nat Comp Canc Netw 2008 Sep; 6(8): 766–94Google Scholar
  102. 102.
    Medscape Medical News. Trabectedin for ovarian cancer rejected by FDA committee [online]. Available from URL: http://www.medscape.com/viewarticle/706350 [Accessed 2010 Jan 20]
  103. 103.
    Medical News Today. FDA issues complete response letter for trabectedin combined with Doxil® [online]. Available from URL: http://www.medicalnewstoday.com/articles/163619.php [Accessed 2010 Jan 20]
  104. 104.

Copyright information

© Adis Data Information BV 2010

Authors and Affiliations

  1. 1.Adis, a Wolters Kluwer BusinessMairangi Bay, North Shore 0754, AucklandNew Zealand

Personalised recommendations